Effect of Postmenopausal Strontium Ranelate Treatment on Oxidative Stress in Rat Skin Tissue

Abstract

Strontium ranelate is one of the most common post-menopausal osteoporosis medications that have been used in recent years. The effects of strontium ranelate treatment on the free radical-antioxidant balance of the skin have not been fully elucidated. In this study, we investigated the effects of strontium ranelate treatment on oxidative stress parameters in the skin tissue of rats with the experimental osteoporosis model. Total 35 rats were divided to five groups as control group (Group I), oophorectomy group (Group II), strontium ranelate group (Group III), oophorectomy + strontium ranelate group (immediately after the oophorectomy) (Group IV) and oophorecto my + strontium ranelat group (after three months of oophorectomy) (Group V). In Group III, IV and V, 500 mg/kg doses of strontium were given to rats by orally. At the end of the study, superoxide dismutase (SOD) and catalase activities, malondialdehyde (MD A) and glutathione (GSH) levels of the rats' skin tissues were determined. Catalase and SOD activities and GSH levels of all groups were significantly lower than Group I (p<0.05). MDA levels of all groups were significantly higher than Group I (p<0.05). Catalase and SOD activities and GSH levels of Group IV and V were significantly lower than Group II (p<0.05). MDA levels of Group IV and V were significantly higher than Group II (p<0.05). In conclusion, strontium ranelate treatment in oophorectomized rats has resulted in an increase in oxidative stress in skin tissue and can cause to several skin disorders.

Hematological and Oxidative Stress Markers Analysis for Detection and Prediction of Osteoporosis in Post-menopausal Women

“…The results showed that serum MDA has a high specificity in ROC statistics, which showed the importance of MDA in the prognostic of osteoporosis. The results found were similar to those observed in the study of Berköz et al . (2017) which showed that serum MDA levels were significantly higher in postmenopausal women with osteoporosis than in the healthy controls.…”